Assembly Biosciences (NASDAQ:ASMB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
Other equities research analysts have also issued reports about the stock. ValuEngine upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Jefferies Group upped their price target on shares of Assembly Biosciences to $75.00 and gave the company a “buy” rating in a report on Thursday, March 8th. B. Riley began coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 price target for the company. Finally, BidaskClub upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, January 30th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $54.25.
In related news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $46.86, for a total transaction of $46,860.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 3,000 shares of company stock valued at $148,270 over the last quarter. 19.60% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Nationwide Fund Advisors purchased a new position in Assembly Biosciences during the 2nd quarter valued at $161,000. Parametric Portfolio Associates LLC increased its position in Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 1,203 shares during the period. Wells Fargo & Company MN purchased a new position in Assembly Biosciences during the 2nd quarter valued at $213,000. The Manufacturers Life Insurance Company increased its position in Assembly Biosciences by 15,448.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 11,123 shares during the period. Finally, Teacher Retirement System of Texas purchased a new position in Assembly Biosciences during the 4th quarter valued at $242,000. Institutional investors own 77.26% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.